Update for investors of

AUROPHARMA

is currently trading at Rs. 1135.50, up by 12.60 points or 1.12% from its previous closing of Rs. 1122.90 on the BSE. The scrip opened at Rs. 1135.05 and has touched a high and low of Rs. 1159.35 and Rs. 1130.25 respectively. So far 62567 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1592.55 on 13-Sep-2024 and a 52 week low of Rs. 994.35 on 07-Apr-2025. Last one week high and low of the scrip stood at Rs. 1159.35 and Rs. 1088.15 respectively. The current market cap of the company is Rs. 66008.10 crore. The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.56% and 6.61% respectively. Aurobindo Pharma’s wholly owned stepdown subsidiary -- Lyfius Pharma has re-started the production at its Penicillin-G manufacturing facility, at Kakinada, Andhra Pradesh (AP), with immediate effect, after receiving the consent to operate (CTO) from Andhra Pradesh from Andhra Pradesh Pollution Control Board (APPCB), on June 29, 2025. Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.